Navigation Links
Lancet study supports new, highly effective treatment for blood disorder
Date:3/20/2009

NEW YORK (March 20, 2009) -- Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health. There are estimated to be between 50,000 and 100,000 individuals in the U.S. diagnosed with chronic immune thrombocytopenic purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, rarely, life-threatening brain hemorrhages.

Promacta (eltrombopag) was granted accelerated approval by the U.S. Food and Drug Administration in November 2008 for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promising results of an international, multicenter Phase III clinical trial, led by NewYork-Presbyterian/Weill Cornell researchers, were the basis of this approval and are published in a recent issue of the Lancet.

"Findings from the new study are very encouraging, and I believe this treatment is an effective option for all patients suffering from chronic ITP," says Dr. James Bussel, principal investigator of the study; attending pediatrician and director of the Program for Platelet Disorders at NewYork-Presbyterian Hospital/Weill Cornell Medical Center; and professor of pediatrics, and professor of pediatrics in medicine at Weill Cornell Medical College.

The study follows a previous Phase II study published late 2007 in the New England Journal of Medicine. This trial showed that eltrombopag was effective in raising platelet counts and lowering bleeding in adult subjects with chronic ITP. The Phase II study's results also determined the most promising dose of 50mg, which was given to all of the experimental subjects in the Phase III study.

The Phase III study tested 114 subjects, who were all 18 years and older, with at least six mont
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
3. Scots and Irish at greater risk of drink-related death, study shows
4. Pilot study shows effectiveness of new, low-cost method for monitoring hand hygiene compliance
5. DOE awards UGA $3.1 million to support complex carbohydrate study nationwide
6. AJCN study shows moderate alcohol consumption related to stronger bones
7. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
8. Study suggests salt might be natures antidepressant
9. Study of protein structures reveals key events in evolutionary history
10. American carnivores evolved to avoid each other, new study suggests
11. Sea Grant awards $820,000 for research under EPAs Long Island Sound study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... of biochemistry and molecular biology at Penn State University, in ... the Nara Institute of Science and Technology in Japan, has ... that acts to prevent it from breeding with itself or ... individuals. In much the same way that human inbreeding sometimes ...
... is available in French . , Which are the ... are the secrets pigs keep from even the most skilled ... new technique that has been developed by McGill University researchers in ... giving industry workers better tools to do their job," explained Dr. ...
... A study funded by the Motor Neurone Disease (MND) Association, ... a common signature of nerve damage in the brains of ... published in the prestigious journal Neurology (2 November 2010). These ... Oxford Study for Biomarkers in MND/ALS (BioMOx). MND research ...
Cached Biology News:To prevent inbreeding, flowering plants have evolved multiple genes, research reveals 2To prevent inbreeding, flowering plants have evolved multiple genes, research reveals 3To prevent inbreeding, flowering plants have evolved multiple genes, research reveals 4Motor Neurone Disease Association study identifies MND biomarker 2
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Significant Environmental Benefits on His Farm , ... St. ... genetically modified (GM) herbicide-tolerant canola crops in the mid-1990s. Today, ... of the canola hectares nationwide to GM canola., , , , ...
... First African Nation Plans to Phase in Routine ... Disease for Infants and Young Children -, ... of Wyeth (NYSE: WYE ), today announced ... pneumococcal,disease with PREVENAR(R) (Pneumococcal Saccharide Conjugated Vaccine,Adsorbed), a ...
... 15 Kinex Pharmaceuticals announced,that David Hsia, Ph.D. ... Dr. Hsia is a pharmaceutical veteran. He ... company listed in New York Stock,Exchange (ticker: WPI). ... Watson Pharmaceuticals before his retirement. He has been,involved ...
Cached Biology Technology:Genetically Modified Canola Plantings Reach 90 Percent in Canada 2Genetically Modified Canola Plantings Reach 90 Percent in Canada 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 2South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 4
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
... B3 series of microscopes offer all of ... for laboratory work. Equipped with Koehler illumination, ... (ASC) objectives. The B3 is the workhorse ... binocular tube eliminates the need for re-focusing ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
RORgamma (S-14)...
Biology Products: